Hipotiroidisme Sentral

01Pathophysiology

Central hypothyroidism (CeH) is a condition of thyroid hormone deficiency that originates not from the thyroid gland itself, but from a failure in the command centers above it: the hypothalamus or the pituitary gland. The thyroid gland is intrinsically normal but is simply not receiving adequate instruction to produce hormone.

Under normal physiology, the hypothalamus secretes thyrotropin-releasing hormone (TRH), which travels via the hypothalamic-hypophyseal portal system to the anterior pituitary. TRH stimulates thyrotroph cells to synthesize and release thyroid-stimulating hormone (TSH). TSH then acts on the thyroid gland via its membrane receptor to promote the synthesis of thyroxine (T4) and, to a lesser extent, triiodothyronine (T3). Circulating T4 and T3 exert negative feedback on both the hypothalamus and the pituitary to maintain hormonal balance.

When the pituitary thyrotrophs are damaged or destroyed (secondary hypothyroidism), TSH production drops. When the hypothalamus fails to produce adequate TRH (tertiary hypothyroidism), the pituitary receives insufficient stimulation and TSH secretion falls as a downstream consequence. In both cases, the result is the same: the thyroid gland is understimulated, and T4/T3 output declines.

A critical concept for exam purposes is that TSH in central hypothyroidism is not elevated. Unlike primary hypothyroidism, where a failing thyroid triggers a compensatory surge in TSH through feedback, in CeH the feedback loop itself is broken at the central level. TSH may be frankly low, but more dangerously, it may be "normal" or even mildly elevated. This occurs because the pituitary may still produce TSH molecules, but they have reduced bioactivity due to abnormal glycosylation patterns. These biologically impotent TSH molecules register on immunoassays but fail to stimulate the thyroid gland effectively. This is why a "normal" TSH in the presence of a low free T4 should never be reassuring if there is clinical suspicion of pituitary or hypothalamic disease.

The clinical presentation is typically milder than primary hypothyroidism for two reasons. First, some residual TSH secretion usually persists, meaning complete thyroid shutdown is rare. Second, the thyroid gland retains some autonomous function independent of TSH. Additionally, patients with CeH almost always have concurrent deficiencies in other pituitary hormones (growth hormone, gonadotropins, ACTH), and the interplay among these deficits can mask or modify symptoms.

A life-threatening complication connects directly to this pathophysiology: levothyroxine accelerates cortisol metabolism. If a patient with unrecognized concurrent ACTH deficiency (secondary adrenal insufficiency) is started on levothyroxine without first correcting the cortisol deficit, the increased metabolic rate will deplete the already limited cortisol reserve, precipitating an adrenal crisis. This is why glucocorticoid replacement must precede thyroid hormone replacement in CeH.

02Classification and Clinical Manifestation

By Anatomic Level

By Onset

By Scope

By System

03Diagnostic Workup

The cornerstone of diagnosis is the combination of a low free T4 with an inappropriately low or normal TSH. This pattern is the biochemical signature of central hypothyroidism. In primary hypothyroidism, a low free T4 drives TSH sharply upward (often >10 mIU/L). In CeH, the TSH fails to mount this compensatory response because the problem lies within the feedback controller itself.

The best initial test when suspecting CeH is a paired measurement of serum free T4 and TSH. Neither test alone is sufficient. If only TSH is measured (as in routine screening), CeH will be missed entirely because TSH appears "normal." This is the single most important teaching point: standard TSH-only screening protocols will not detect this condition. Free T4 must be measured.

When the biochemical pattern is identified (low free T4 with non-elevated TSH), the next step is to determine the cause. An MRI of the sella turcica with and without gadolinium contrast is the gold standard imaging study. It will reveal structural lesions such as pituitary macroadenomas, craniopharyngiomas, empty sella (as seen in Sheehan syndrome), or infiltrative processes.

Simultaneously, a full anterior pituitary hormone assessment should be obtained. This includes morning cortisol (or ACTH stimulation testing), LH, FSH, prolactin, IGF-1 (as a surrogate for GH status), and sex steroids. The rationale is that CeH rarely occurs in isolation. If one pituitary hormone axis is compromised, others are likely affected. The most dangerous concurrent deficiency is ACTH deficiency, which must be identified and treated before thyroid hormone replacement begins.

The TRH stimulation test, in which exogenous TRH is administered intravenously and serial TSH measurements are taken, was historically used to differentiate pituitary from hypothalamic causes. A blunted or absent TSH rise suggests pituitary damage, while a delayed but eventually normal TSH rise suggests hypothalamic TRH deficiency. However, the 2016 Endocrine Society guidelines and the 2018 European Thyroid Association guidelines recommend against routine use of this test, as it does not reliably change clinical management. TRH is also not commercially available in many countries.

An important adjunct to the diagnosis is evaluating the clinical context. A history of pituitary surgery, cranial irradiation, postpartum hemorrhage with failure to lactate (Sheehan syndrome), traumatic brain injury, or recent use of bexarotene or immune checkpoint inhibitors (ipilimumab/nivolumab-related hypophysitis) should heighten clinical suspicion significantly.

04Management and Treatment

Before anything else, cortisol status must be confirmed. This is the highest-yield management principle in CeH. If a patient with pituitary disease has an unrecognized cortisol deficiency and is started on levothyroxine, the increase in metabolic rate will accelerate cortisol clearance and precipitate a potentially fatal adrenal crisis (acute hypotension, shock, altered consciousness). The rule is absolute: glucocorticoids first, then levothyroxine. If cortisol status cannot be rapidly determined, empiric hydrocortisone coverage (stress-dose steroids) should be given before initiating thyroid replacement.

Once cortisol is either confirmed adequate or is being replaced, levothyroxine (L-T4) is the first-line treatment. The standard replacement dose in adults is approximately 1.6 mcg/kg/day. In healthy younger adults, this translates to roughly 75 to 150 mcg daily. In older adults (age 65 and above) or patients with underlying cardiac disease, the starting dose should be lower, approximately 1.0 mcg/kg/day (often 25-50 mcg/day), with gradual uptitration every 4-6 weeks to avoid cardiac complications.

For neonates with congenital CeH, treatment must begin within 2 weeks of birth at doses comparable to those used in primary congenital hypothyroidism: 10-15 mcg/kg/day. Delay in treatment risks irreversible neurodevelopmental damage.

A critical difference from primary hypothyroidism is how treatment is monitored. In primary hypothyroidism, TSH is the monitoring parameter. In CeH, TSH is unreliable and must not be used to guide dose adjustments. TSH may remain low or undetectable regardless of whether the patient is adequately replaced. Instead, the monitoring parameter is serum free T4, with the target being the upper half of the normal reference range (roughly above the midpoint). Some experts advocate targeting a free T4 just above the 50th percentile of the reference interval.

Free T4 and TSH should be rechecked 6 to 8 weeks after any dose change. Long-term follow-up typically includes free T4 measurement every 6-12 months once stable dosing is achieved.

Several conditions require dose adjustments:

• Initiation of GH replacement therapy: GH enhances peripheral conversion of T4 to T3, increasing thyroid hormone clearance. Patients who start GH may develop worsening hypothyroidism and require an increase in L-T4 dose.

• Initiation or change in estrogen therapy: Oral estrogens increase thyroxine-binding globulin (TBG), reducing free T4 levels and necessitating a higher L-T4 dose.

• Pregnancy: L-T4 requirements increase by approximately 30-50%, and close monitoring of free T4 is essential throughout gestation.

Combination T4/T3 therapy has not demonstrated superiority over L-T4 monotherapy in CeH according to current evidence, and is generally not recommended as standard practice.

Treatment of the underlying cause (e.g., transsphenoidal surgery for a pituitary adenoma, radiation, dopamine agonists for prolactinoma) is pursued in parallel. However, even after successful treatment of the primary lesion, many patients will require lifelong thyroid hormone replacement.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students and test-takers get central hypothyroidism questions wrong is by relying on TSH alone to exclude hypothyroidism. The entire premise of CeH is that TSH is unreliable. A vignette will describe a patient with fatigue, cold intolerance, and weight gain, whose labs show a "normal" TSH. The unwary student marks this as "euthyroid" or "no thyroid disease." The correct move is to recognize the clinical suspicion and check free T4. When the question stem includes a history of pituitary surgery, cranial radiation, postpartum hemorrhage, or head trauma, the test-writer is handing you the context to think beyond standard screening.

The second trap involves the treatment sequencing question. A vignette will present a patient newly diagnosed with panhypopituitarism (low cortisol, low free T4, low gonadotropins). The question asks "what is the next best step in management?" The wrong answer is "start levothyroxine." The correct answer is "replace glucocorticoids first." Starting L-T4 without cortisol coverage can kill the patient. This cortisol-first principle is tested repeatedly because it integrates knowledge of multiple endocrine axes and demands understanding of the physiological interaction between thyroid hormone and cortisol metabolism.

The third trap is the goiter question. If a vignette describes a patient with hypothyroidism and a goiter, this effectively rules out central hypothyroidism. In CeH, the thyroid gland is understimulated and therefore normal or atrophic. A goiter implies TSH-driven thyroid hyperplasia, which only occurs in primary disease or in the rare syndrome of thyroid hormone resistance. This is a built-in discriminator that test-writers use to steer you toward or away from CeH.

A fourth pearl involves Sheehan syndrome as the classic female-centered vignette for CeH. The setup will describe a woman with a history of complicated delivery with significant blood loss, followed by failure to lactate (agalactia) and failure to resume menstruation (amenorrhea). Years later, she presents with fatigue and is found to have panhypopituitarism. MRI shows an empty sella. The answer to "what is the underlying diagnosis" is Sheehan syndrome, and the answer to "what must be corrected before thyroid replacement" is adrenal insufficiency.

Finally, be aware of bexarotene as a drug-induced cause of CeH. This retinoid X receptor agonist, used in cutaneous T-cell lymphoma, directly suppresses TSH-beta gene transcription and increases peripheral thyroid hormone metabolism. The question stem will mention a patient on treatment for a skin lymphoma who develops hypothyroid symptoms with a suppressed TSH. The answer is drug-induced central hypothyroidism, and the management is levothyroxine at doses that may be substantially higher than usual (up to 2-3 times the weight-based dose) because bexarotene simultaneously accelerates thyroid hormone clearance.

The core competency being tested with CeH is the student's ability to interpret thyroid function tests in context rather than in isolation, to recognize that a "normal" lab value can be pathological when the clinical setting demands a different result, and to correctly sequence the management of multiple concurrent endocrine deficiencies.